Must be BMY Opdivo failure that is leading them to the conclusion that they must have PS Targeting in a combo in order to have a chance
Imagine that, BMY failed to realize that only 20-30% of the patients in the trials responded to Opdivo ? 20-30%? that is the biggest failure
It is now Peregrine that has a blood test in the works, to prove which patients will benefit from PS Targeting--- now I wonder why BMY wouldn't move forward with a blood test ? LOL
Because if they ever declared their blood test, it would PROVE that PS Targeting is required
The biggest failure of all was BMY and now it may be too late to bring PS Targeting into Opdivo, because Memorial Sloan Kettering and Dr. Jedd Wolchok may show there is a better way
They've made $300k to $500k per year for the past fifteen years to fail, so they are in no particular hurry. They can milk this for another fifteen years easy once the reverse split happens. Many shareholders on this board are delighted with the job they are doing.
Science DOES FAIL...that is why Science Advances and Learns. As for Peregrine... Management and BOD are complete failures and they sure seem to be taking their time learning from their failures